UOC
STRO icon

UBS O'Connor’s Sutro Biopharma STRO Stock Holding History

UBS O'Connor’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,828
Closed -$18.4K – 450
2025
Q1 		$18.4K Sell
2,828
-27,234
-91% -$429K ﹤0.01% 302
2024
Q4 		$553K Sell
30,062
-3,760
-11% -$115K 0.01% 274
2024
Q3 		$1.17M Buy
33,822
+6,316
+23% +$248K 0.03% 259
2024
Q2 		$806K Buy
27,506
+2,000
+8% +$79.1K 0.02% 328
2024
Q1 		$1.44M Sell
25,506
-12,328
-33% -$545K 0.04% 237
2023
Q4 		$1.62M Buy
37,834
+4,834
+15% +$153K 0.05% 207
2023
Q3 		$1.15M Buy
+33,000
New +$1.44M 0.02% 317
2022
Q2 		– Sell
-12,000
Closed -$986K – 1000
2022
Q1 		$986K Buy
+12,000
New +$1.14M 0.01% 701

Other funds holding STRO

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

UBS O'Connor's STRO Position: Q2 2025 in Review

UBS O'Connor sold out of Sutro Biopharma (STRO) in Q2 2025, closing a stake of 2,828 shares — an estimated $18.4K sold.

UBS O'Connor first reported a position in STRO in Q1 2022 and held it in 8 quarters. The position peaked at $1.62M in Q4 2023. 99 funds tracked by Wall St. Rank hold STRO as of Q2 2025.

  • UBS O'Connor reported no remaining Sutro Biopharma position as of Q2 2025 after selling out during the quarter.
  • UBS O'Connor sold 2,828 Sutro Biopharma shares in Q2 2025, an estimated $18.4K.
  • UBS O'Connor first reported a position in Sutro Biopharma in Q1 2022 and held it in 8 quarters.
  • UBS O'Connor's Sutro Biopharma position peaked at $1.62M in Q4 2023.
  • 99 funds tracked by Wall St. Rank held Sutro Biopharma as of Q2 2025.

Based on UBS O'Connor's 13F filing for Q2 2025, filed 14 Aug 2025.